NCT00144482View on ClinicalTrials.gov

A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

March 31, 2005

Study Completion Date

August 31, 2005

Conditions
Chemotherapy Induced Anemia
Interventions
DRUG

recombinant human erythropoietin

36000IU（0.5mL）s.c./week for 8 weeks

DRUG

recombinant human erythropoietin placebo

0 IU(0.5mL)s.c./week for 8 weeks

Sponsors
All Listed Sponsors
lead

Chugai Pharmaceutical

INDUSTRY

NCT00144482 - A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy | Biotech Hunter | Biotech Hunter